MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(MARKET WIRE)--Aug 1, 2007 -- Living Cell Technologies Limited (ASX:LCT.AX - News) today announced that the enhanced longevity of its advanced biocapsule formula, currently being tested in a Phase I/IIa clinical trial for type I diabetes, was highlighted in a study published by Journal of BioMedical Materials Research Part A, a leading publication focused on the materials science aspect of drug delivery systems.
